Therefore, implementing a treatment plan with the goal of de-intensifying antidiabetic treatment by switching antidiabetic agents to SGLT2 inhibitors could be beneficial in patients with HF and T2D. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.